Edition:
United Kingdom

Shire PLC (SHPG.OQ)

SHPG.OQ on NASDAQ Stock Exchange Global Select Market

144.99USD
19 Jan 2018
Change (% chg)

$-0.70 (-0.48%)
Prev Close
$145.69
Open
$145.90
Day's High
$146.05
Day's Low
$143.54
Volume
382,779
Avg. Vol
373,557
52-wk High
$192.15
52-wk Low
$137.20

Select another date:

Fri, Jan 19 2018

BRIEF-Shire Says ‍Thomas Dittrich Will Assume Role As CFO

* ‍THOMAS DITTRICH WILL ASSUME HIS ROLE AS CHIEF FINANCIAL OFFICER​

BRIEF-Shire Says Granted EU marketing Authorization For ADYNOVI For Adults And Adolescents With Hemophilia A

* SHIRE GRANTED EU MARKETING AUTHORIZATION FOR ADYNOVI [ANTIHEMOPHILIC FACTOR (RECOMBINANT), PEGYLATED] FOR ADULTS AND ADOLESCENTS WITH HEMOPHILIA A​

Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

LONDON Shire ditched its revenue target of $20 billion by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.

Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

LONDON Shire ditched its revenue target of $20 billion (14.8 billion pounds) by 2020 on Monday due to increased generic competition and new drugs from rivals, saying it would split its rare disease and hyperactivity medicines businesses to boost performance.

UPDATE 2-Shire cuts 2020 revenue target, prepares for spin-off of ADHD drugs

* Shares fall 6 percent (Adds CEO comments, analyst reaction, closing share price)

Shire to separate ADHD drugs ahead of possible spin-off, cuts outlook

LONDON, Jan 8 London-listed pharmaceutical group Shire said on Monday it would create two distinct business units for its rare disease and hyperactivity medicines ahead of deciding later this year whether to spin off the latter into a separately listed group.

BRIEF-Shire Says Xiidra Approved By Health Canada To Treat Signs And Symptoms Of Dry Eye Disease

* XIIDRA APPROVED BY HEALTH CANADA TO TREAT SIGNS AND SYMPTOMS OF DRY EYE DISEASE

BRIEF-Shire Files For FDA Approval Of New Plasma Manufacturing Facility In Covington, Georgia

* SHIRE FILES FOR FDA APPROVAL OF A NEW PLASMA MANUFACTURING FACILITY IN COVINGTON, GEORGIA TO SUPPORT GROWING IMMUNOLOGY FRANCHISE

Shire's Hunter syndrome drug fails late-stage study

Shire Plc's experimental treatment for children with Hunter syndrome and cognitive impairment failed to meet the main and secondary goals of a late-stage clinical trial.

UPDATE 1-Shire's Hunter syndrome drug fails late-stage study

Dec 19 Shire Plc's experimental treatment for children with Hunter syndrome and cognitive impairment failed to meet the main and secondary goals of a late-stage clinical trial.

Select another date: